BIOS BioSenic S.A.
BioSenic S.A., a biotechnology company, develops cell therapy products and treatments for autoimmune and inflammatory diseases in Belgium and France. The company offers arsenic trioxide (ATO) and oral arsenic trioxide (OATO) platforms. It also provides medicinal products, including ArsciMed, an intravenous drug to treat autoimmune diseases. In addition, the company develops 4P004v which is in Phase I clinical trial for veterinary use. BioSenic S.A. is headquartered in Saintes, Belgium.…
Industry Peers
BiotechnologyKey Statistics
About BioSenic (EBR: BIOS)
›
BioSenic (EBR: BIOS) is listed on Euronext Brussels, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 7 employees.
The shares were at 0.0020 EUR on 18 November 2026, down 16.7% over 52 weeks. Its 52-week range is 0.0018 EUR to 0.0026 EUR: the price is 23.1% below the high and 11.1% above the low.
Its market capitalisation is 1.31M EUR.
BioSenic reports return on equity of 125.6% and an operating margin of 210.1%.
Its debt exceeds its cash by 2.44M EUR. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health.